• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Barron's Top Weekend Stock Picks: Costco, Johnson & Johnson, And How Tesla Could Become A Value Stock

    12/24/22 12:17:57 PM ET
    $COP
    $COST
    $HES
    $JNJ
    Integrated oil Companies
    Energy
    Department/Specialty Retail Stores
    Consumer Discretionary
    Get the next $COP alert in real time by email

    Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.

    "Robots Are Replacing Workers Lost in the Pandemic. They’re Here to Stay," by Daren Fonda, explains how labor shortages and rising wage costs are helping spur a new generation of robots that can handle a variety of basic job tasks.

    In "Can Tesla Be a Value Stock? How It’s Going to Get There," Al Root writes that Tesla Inc's (NASDAQ:TSLA) stock is trading for 22 times estimated 2023 earnings (its lowest P/E ratio ever), and it's beginning to look attractive to value investors.

    "Love a Sale? It’s a Great Time to Buy Costco Stock," by Tereas Rivas, notes that although Costco Wholesale Corp (NASDAQ:COST) stock has fallen 18% this year, the outlook for 2023 is better for the warehouse-store giant, whose loyal customers continue buying its bargain-priced goods.

    In "6 Defensive Healthcare Stocks for 2023," Josh Nathan-Kazis writes that as investors continue to navigate market uncertainty, large-cap healthcare stocks remain an attractive defensive play, including UnitedHealth Group Inc (NYSE:UNH) and Johnson & Johnson (NYSE:JNJ) which are up 5.78% and 3.46%, respectively.

    "Energy Stocks Hess and ConocoPhillips Rise as Oil Prices Surge," by Emily Dattilo, reports that energy stocks, like ConocoPhillips (NYSE:COP) and Hess Corp (NYSE:HES) were rising on Friday after Russia indicated it may reduce oil production in response to price caps placed on its exports.

    In "Rising Prices Have Shoppers Buying Secondhand Gifts," Sabrina Escobar writes that many shoppers are looking to save money by buying pre-owned luxury goods this holiday season, and many are turning to retailers like RealReal Inc (NASDAQ:REAL) and Poshmark Inc (NASDAQ:POSH).

    See Also: Apple Bans TikTok? Netflix Merger? 7 Bold Tech Predictions For 2023

    At the time of this writing, the author had no position in the mentioned equities.

    Get the next $COP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COP
    $COST
    $HES
    $JNJ

    CompanyDatePrice TargetRatingAnalyst
    ConocoPhillips
    $COP
    2/17/2026$112.00Buy → Neutral
    Roth Capital
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    ConocoPhillips
    $COP
    1/20/2026$98.00Overweight → Neutral
    Analyst
    ConocoPhillips
    $COP
    1/16/2026$102.00Neutral → Underperform
    BofA Securities
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    ConocoPhillips
    $COP
    1/12/2026$132.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $COP
    $COST
    $HES
    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ConocoPhillips downgraded by Roth Capital with a new price target

    Roth Capital downgraded ConocoPhillips from Buy to Neutral and set a new price target of $112.00

    2/17/26 8:12:52 AM ET
    $COP
    Integrated oil Companies
    Energy

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Analyst reiterated coverage on Tesla with a new price target

    Analyst reiterated coverage of Tesla with a rating of Underweight and set a new price target of $145.00 from $150.00 previously

    1/30/26 8:00:23 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $COP
    $COST
    $HES
    $JNJ
    SEC Filings

    View All

    SEC Form 10-K filed by ConocoPhillips

    10-K - CONOCOPHILLIPS (0001163165) (Filer)

    2/17/26 11:32:24 AM ET
    $COP
    Integrated oil Companies
    Energy

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/13/26 4:24:01 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Johnson & Johnson

    S-3ASR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 5:24:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COP
    $COST
    $HES
    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COP
    $COST
    $HES
    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

    More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients  78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement)STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 compa

    2/21/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

    Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of careRARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated. Data were presented during a plenary session at the 2026 Multid

    2/19/26 5:00:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The RealReal Reopens its Flagship San Francisco Store in Union Square for Shopping and Consignment

    SAN FRANCISCO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The RealReal (NASDAQ:REAL), the world's largest marketplace for authenticated luxury resale, today announced the reopening of its San Francisco flagship store in the heart of Union Square — reaffirming the company's deep roots in the city where it was founded and its commitment to San Francisco's downtown revival. The store officially opens on Thursday, February 26, at 11:00 a.m. PT for consignment and shopping. The reopening marks The RealReal's 17th retail location nationwide and introduces a fully reimagined, two-story flagship spanning more than 8,100 square feet. Designed as a destination for both shopping and consignment, the expanded

    2/18/26 11:00:00 AM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    $COP
    $COST
    $HES
    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcraven William H. bought $500,000 worth of shares (5,768 units at $86.68) (SEC Form 4)

    4 - CONOCOPHILLIPS (0001163165) (Issuer)

    11/10/25 6:12:56 PM ET
    $COP
    Integrated oil Companies
    Energy

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Executive Vice President Johnson Kirk L. bought $499,472 worth of shares (5,300 units at $94.24), increasing direct ownership by 57% to 14,527 units (SEC Form 4)

    4 - CONOCOPHILLIPS (0001163165) (Issuer)

    6/17/25 11:47:06 AM ET
    $COP
    Integrated oil Companies
    Energy

    $COP
    $COST
    $HES
    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CIO Swanson James D. sold $15,109,759 worth of shares (62,080 units at $243.39), exercised 73,140 shares at a strike of $139.50 and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 36% to 25,698 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:32 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief TO and Risk Officer Wengel Kathryn E covered exercise/tax liability with 7,266 shares and converted options into 15,598 shares, increasing direct ownership by 8% to 114,288 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:26 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief HR Officer Mulholland Kristen converted options into 5,006 shares and covered exercise/tax liability with 1,585 shares, increasing direct ownership by 21% to 19,830 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COP
    $COST
    $HES
    $JNJ
    Financials

    Live finance-specific insights

    View All

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Impactive Capital Nominates Four Candidates to WEX Board

    Contends Board Level Change is Required to Address Alarming Share Price Underperformance, Culture of Entrenchment and Widening Valuation Gap Versus Its Closest Peer Nominees Kurt Adams, Ellen Alemany, Ken Cornick and Lauren Taylor Wolfe Each Bring an Owner's Perspective and the Relevant Industry Experience to Strengthen Strategic Oversight, Enhance Capital Allocation and Improve Operational Performance Nominees Have Demonstrated Conviction in WEX's Value Potential and Personally Purchased More Shares Than the Entire Incumbent Board Over the Past Nine Years Impactive Capital, LP, ("Impactive" or "we") together with its affiliates, one of the largest shareholders of WEX Inc. (NYSE:WEX)

    2/9/26 8:00:00 AM ET
    $ADP
    $CLVT
    $CPAY
    Diversified Commercial Services
    Industrials
    EDP Services
    Technology

    ConocoPhillips reports fourth-quarter and full-year 2025 results; announces 2026 guidance and quarterly dividend

    Reported fourth-quarter 2025 earnings per share of $1.17 and adjusted earnings per share of $1.02. Provided 2026 guidance, including full-year capital expenditures of approximately $12 billion and full-year adjusted operating costs of $10.2 billion. Declared first-quarter 2026 ordinary dividend of $0.84 per share. ConocoPhillips (NYSE:COP) today reported fourth-quarter 2025 earnings of $1.4 billion, or $1.17 per share, compared with fourth-quarter 2024 earnings of $2.3 billion, or $1.90 per share. Excluding special items, fourth-quarter 2025 adjusted earnings were $1.3 billion, or $1.02 per share, compared with fourth-quarter 2024 adjusted earnings of $2.4 billion, or $1.98 per sh

    2/5/26 7:00:00 AM ET
    $COP
    Integrated oil Companies
    Energy

    $COP
    $COST
    $HES
    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by The RealReal Inc.

    SC 13D - TheRealReal, Inc. (0001573221) (Subject)

    11/1/24 9:00:48 AM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by The RealReal Inc.

    SC 13G/A - TheRealReal, Inc. (0001573221) (Subject)

    10/1/24 4:17:51 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    SEC Form SC 13G filed by The RealReal Inc.

    SC 13G - TheRealReal, Inc. (0001573221) (Subject)

    9/5/24 4:09:09 PM ET
    $REAL
    Other Specialty Stores
    Consumer Discretionary

    $COP
    $COST
    $HES
    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care